Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study

Zheng, Yan; Li, Yin; Liu, Xianben; Zhang, Ruixiang; Wang, Zongfei; Sun, Haibo; Liu, Shilei

doi:10.7150/jca.29353



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2019; 10(5):1097-1102. doi:10.7150/jca.29353 This issue Cite

Research Paper

Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study

Yan Zheng^*, Yin Li^*,✉, Xianben Liu, Ruixiang Zhang, Zongfei Wang, Haibo Sun, Shilei Liu

Department of Thoracic Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Zhengzhou, Henan 450008, P. R. China
^*Yan Zheng, and ^*Yin Li contributed equally to this article.

Citation:

Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. J Cancer 2019; 10(5):1097-1102. doi:10.7150/jca.29353. https://www.jcancer.org/v10p1097.htm

Other styles

Abstract

There is no consensus about the combined therapeutic strategy for esophageal squamous cell carcinoma in China. The quality control and standardization of surgery procedures were far from satisfactory in past neoadjuvant chemotherapy trials, which may underestimate the survival benefits. Therefore, we tried to evaluate the survival benefit of paclitaxel plus platinum followed by minimally invasive esophagectomy with total two-field lymphadenectomy patterns versus primary surgery. Between 06/2011 and 12/2014, there were 279 consecutive patients who underwent minimally invasive esophagectomy with total two-field lymphadenectomy; 83 received neoadjuvant chemotherapy and 196 primary surgery. Propensity score matching was used to compare neoadjuvant chemotherapy patients and 76 matched primary surgery patients. Effectiveness of neoadjuvant chemotherapy, adverse events, complications after the operation, and survival rates were evaluated. After propensity score matching, and compared with primary surgery, neoadjuvant chemotherapy was significantly associated with a better survival (P = 0.049). The overall clinical response rate of neoadjuvant chemotherapy was 77.1%. The pathological response rate was 20.5%. There was no significant difference in complication rates between two groups. Neoadjuvant chemotherapy with paclitaxel plus platinum followed by minimally invasive esophagectomy and total two-field lymphadenectomy have better OS over the primary surgery without serious adverse events.

Keywords: minimally invasive esophagectomy, neoadjuvant chemotherapy, survival

Citation styles

APA

Zheng, Y., Li, Y., Liu, X., Zhang, R., Wang, Z., Sun, H., Liu, S. (2019). Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. Journal of Cancer, 10(5), 1097-1102. https://doi.org/10.7150/jca.29353.

ACS

Zheng, Y.; Li, Y.; Liu, X.; Zhang, R.; Wang, Z.; Sun, H.; Liu, S. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. J. Cancer 2019, 10 (5), 1097-1102. DOI: 10.7150/jca.29353.

NLM

CSE

Zheng Y, Li Y, Liu X, Zhang R, Wang Z, Sun H, Liu S. 2019. Neoadjuvant chemotherapy followed by minimally invasive esophagectomy versus primary surgery for management of esophageal carcinoma: a retrospective study. J Cancer. 10(5):1097-1102.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.